Human Genome Sciences, Inc. to Seek Hepatitis Drug Approval in Q4

Bookmark and Share

Reuters -- Human Genome Sciences Inc and its partner Novartis will seek approval for their experimental hepatitis C drug in the fourth quarter, Human Genome said on Monday.

MORE ON THIS TOPIC